Information Technology [ 8/12 ] | Semiconductors & Semiconductor Equipment [ 18/74 ]
NASDAQ | Common Stock
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally.
It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies.
It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 10, 26 | 0.94 Increased by +135.67% | - |
| Nov 28, 25 | -2.49 Decreased by -120.06% | - |
| Sep 2, 25 | -2.60 Increased by +39.67% | - |
| May 7, 25 | 4.31 Increased by +1.02 K% | - |
| Feb 26, 25 | -2.64 Increased by +89.02% | - |
| Nov 22, 24 | 12.39 Increased by +1.45 K% | - |
| Jul 2, 24 | -4.31 Decreased by -288.25% | - |
| May 15, 24 | -0.47 Increased by +56.88% | -0.62 Increased by +24.19% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 487.67 K Increased by +136.73% | 3.57 M Increased by +259.97% | Increased by +731.49% Increased by +167.57% |
| Sep 30, 25 | 277.29 K Increased by +65.05% | -2.12 M Decreased by -120.28% | Decreased by -764.49% Decreased by -112.28% |
| Jun 30, 25 | 386.50 K Increased by +36.09% | -2.07 M Increased by +10.98% | Decreased by -534.80% Increased by +34.59% |
| Mar 31, 25 | 386.50 K Increased by +N/A% | -2.07 M Increased by +4.26% | Decreased by -534.80% Decreased by N/A% |
| Dec 31, 24 | 206.00 K Increased by +N/A% | -2.23 M Increased by +4.29% | Decreased by -1.08 K% Decreased by N/A% |
| Sep 30, 24 | 168.00 K Increased by +N/A% | 10.46 M Increased by +236.50% | Increased by +6.22 K% Decreased by N/A% |
| Jun 30, 24 | 284.00 K Increased by +N/A% | -2.32 M Increased by +38.28% | Decreased by -817.61% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.16 M Increased by +38.58% | Decreased by N/A% Decreased by N/A% |